ERBB2-eiwit (C-human IgG1-Fc, mens)

ERBB2

C-ERB-2, c-ERB2, CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, MLN19, NEU, NGL, p185 (erbB2), TKR1, VSCN2

C-human IgG1-Fc

< 1.0 EU per μg of the protein as determined by the LAL method

≥ 90 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC. ≥ 90 % as determined by SEC-MALS (Routinely tested) .

1. Immobilized Recombinant Human HER2 / ErbB2 Protein (Fc Tag) (Cat: 10004-H02H) at 0.05 μg/mL (100 μL/well) can bind Trastuzumab derived Anti-Erbb2 antibody, Human IgG1, the EC50 is 10.2-30.8 ng/mL (QC tested) . 2. Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.5-3 μg/mL in the presence of 0.6 μg/mL Anti-ErbB2/Her2 Monoclonal Antibody (Routinely tested) .

Met1-Thr652

The recombinant human ErbB2/Fc chimera is a disulfide-linked homodimeric protein generated by proteolytic removal of the signal peptide. The monomer comprises 868 amino acids and has a calculated molecular mass of 96.1 kDa. As a result of glycosylation, the monomer migrates as an approximately 130-140 kDa protein in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 218.9 kDa verified by SEC-MALS (Routinely tested) .

Human